Shares of pharmaceutical biotechnology company Corcept Therapeutics Inc. (NASDAQ stock symbol CORT) closed at $4.10 a share on Tuesday, the highest level since September 2007.
Corcept Therapeutics Incorporated is engaged in the discovery and development of drugs for the treatment of psychiatric disorders as well as metabolic issues. CORT is engaged in the development of drugs for disorders that are associated irregular levels of cortisol, a steroid hormone.
Corcept Therapeutics' lead product is CORLUX. CORLUX is glucocorticoid receptor II (GR-II) antagonist. CORLUX is in Phase III clinical trials for the treatment of Cushing's Syndrome and psychotic depression.
Corcept Therapeutics CORT stock price quote
